Although there is limited evidence for PD, a study by Novak and colleagues showed that intranasal short-acting (regular) insulin treatment improved motor performance and function compared to placebo, resulting in lower disability scores (Hoehn and Yahr scale) and improved Unified Parkinson’s Disease rating scale (UPDRS) motor scores compared to placebo [89]. This evidence concerns the gene INS and Parkinson disease.